1. Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial 
Jennifer L. Furman, Abigail Soyombo, Andrew H. Czysz, Manish K. Jha, Thomas J. Carmody, Brittany L. Mason, Philipp E. Scherer, Madhukar H. Trivedi 
Personalized Medicine in Psychiatry  
Volume 9, Pages 1-7 (August 2018)
DOI: /j.pmip
Copyright © 2018 Elsevier Inc. Terms and Conditions

2. Fig. 1
Moderating effect of adiponectin between combination therapies. Patients with a low level of baseline adiponectin (25th percentile) respond better to escitalopram plus bupropion therapy than venlafaxine plus mirtazapine therapy (A). Patients with a high level of baseline adiponectin (75th percentile) respond better to venlafaxine plus mirtazapine therapy than escitalopram plus bupropion (B).
Personalized Medicine in Psychiatry  2018 9, 1-7DOI: ( /j.pmip )
Copyright © 2018 Elsevier Inc. Terms and Conditions

3. Fig. 2
Conceptual model for the moderating effect of adiponectin. Adiponectin levels are reportedly altered in depression and associated metabolic disorders (A) which may be explained by changes in several biological features (B). In participants with relatively low adiponectin levels, escitalopram plus bupropion therapy may be superior because it can ameliorate symptoms associated with low adiponectin, such as inflammation and low monoamine signaling. In participants with relatively high adiponectin levels, venlafaxine plus mirtazapine may be superior because it can promote weight gain, which may decrease adiponectin (C).
Personalized Medicine in Psychiatry  2018 9, 1-7DOI: ( /j.pmip )
Copyright © 2018 Elsevier Inc. Terms and Conditions